Advertisement

Topics

FDA Grants Pembrolizumab Priority Review for HCC

16:59 EDT 11 Jul 2018 | OncLive

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced hepatocellular carcinoma 

Original Article: FDA Grants Pembrolizumab Priority Review for HCC

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Pembrolizumab Priority Review for HCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...